Answers are grounded in this paper and cite their sources.
We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane, Embase, and Clinicaltrials.gov. After screening 626 articles, eight studies were included. Data were extracted following the PRISMA guidelines and analyzed using the meta-package by Schwarzer et al. We analyzed 540 patients. The pooled median 3 (1−5) year overall survival was 21% (95% CI 0.08–0.37, I2=91%, n=540). The pooled relapse rate was 58.9% (95% CI 0.38–0.77, I2=93%, n=487) at a median of 1.75 (1−3) years. The pooled 4-year progression- free survival was 34.8% (95% CI 0.15–0.57, I2=72%, n=105). Outcomes of Allo-HSCT for TP53-mutated MDS patients remain poor, with 21% OS at three years; however, Allo-HSCT confers a survival advantage as compared to non-transplant palliative therapies. Our findings suggest the need to explore novel therapeutic agents in prospective clinical trials. • Outcomes of Allo-HSCT for TP53-mutated MDS patients remain poor with a three-year survival of 21%. • HSCT confers a survival advantage as compared to non-transplant palliative therapies. • Our findings suggest the need to explore novel therapeutic agents in prospective clinical trials.
No takes yet. Share an insight, caveat, or question.
Shahzad et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: